Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones
Go back to Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones| Merck & Co. (NYSE: MRK) | Delayed: 148.46 -1.87 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.33 | 52 Week High | $65.46 | |||
| Open | $148.41 | 52 Week Low | $47.97 | |||
| Day High | $149.60 | P/E | 100.99 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 11,187,248 | |||||
| (NYSE: OGN) | Delayed: 13.75 -0.03 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.78 | 52 Week High | $8.00 | |||
| Open | $13.77 | 52 Week Low | $8.00 | |||
| Day High | $13.78 | P/E | N/A | |||
| Day Low | $13.75 | EPS | $0.00 | |||
| Volume | 1,629,816 | |||||
